Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dynamic Markets Need Dynamic Pricing: Roche Explores Differential Pricing Strategies In Emerging Markets

This article was originally published in PharmAsia News

Executive Summary

Roche experiments with a variety of tactics, including second brands, patient assistant programs, supporting private insurance and other ways to drive volume in highly fragmented markets.

You may also be interested in...



Insider Analysis From Easton Associates: Are Patient Assistance Programs The Silver Bullet To Meet Affordability Challenges In China?

By Celia Deng, Zhiyi Tong and Paul Zhang

BMS Benefits From Focused Strategy, Novartis Looks To Vaccines; Abbott Tries To Educate U.S. Investors: Emerging Markets Earnings Roundup (Part 2)

Emerging markets remained a key focus of Big Pharma during first quarter earnings calls, with many highlighting exceptional growth in these markets, particularly China. Others talked at length about commercial strategy and sales force expansion, with some companies like Bristol-Myers Squibb Co. hyping the virtues of staying true to its innovative roots, while others like Novartis AG talked up the value of diversification. And Abbott Laboratories, in its continuing quest to "educate" U.S. investors about emerging markets, decided for a wholesale change in how it reports its business, although the initial reaction from at least one analyst might have caught the company off guard.

Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets? (Part 2 of 2)

[Editor's note: This is part two of a two-part story; part one appeared in PharmAsia News, March 4, 2011.]

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel